Conciseness

The bulk of the body is non-derivable, earned content — exact tool names, parameter quirks ('`smiles` must be a list', 'SMILES must contain `[*{min-max}]`'), fallback chains, and runtimes. Minor padding a pass would trim: the Binding Site Reasoning section explains structural biology Claude already knows ('deep, well-defined pockets. Classic small molecule territory'; 'Nuclear receptors: deep hydrophobic pockets'), the KEY PRINCIPLES list restates later sections, and the '(requires NVIDIA_API_KEY env var; free key at build.nvidia.com)' note repeats five times. This fits anchor 4's 'minor instances of over-explanation' better than anchor 3's 'some unnecessary explanation', but not anchor 5's 'every token earns its place'.

Actionability

Mostly copy-paste-ready guidance: 'ChEMBL_search_targets(pref_name__contains=target_name, organism="Homo sapiens")', 'NvidiaNIM_genmol(smiles="...core...[*{3-8}]...tail...[*{1-3}]...", num_molecules=100, temperature=2.0, scoring="QED")', specific cutoffs (IC50/Ki/Kd < 10 uM, QED > 0.3, MW 200-600), and a fully executable Programmatic Access section. Not a 5: 'NvidiaNIM_boltz2(polymers=[...], ligands=[...])' is an abbreviated sketch, and report initialization defers to 'all section headers from the template (see REPORT_TEMPLATE.md)' — a file absent from the bundle. Well above anchor 3's 'pseudocode instead of executable code'.

Workflow Clarity

Phases 0-7 are explicitly ordered with validation checkpoints throughout: verify tool parameters before calling unfamiliar tools ('Common parameter corrections (verify with `get_tool_info` if uncertain)'), 'Dock a known reference inhibitor first to validate the binding pocket geometry before running candidates', pLDDT gates ('<70 use with caution'), decision points ('If no tractability data... explicitly warn the user before proceeding'), a filter funnel summary, and a pre-delivery CHECKLIST.md invocation, plus fallback chains for every step. This matches anchor 5's 'explicit validation steps; feedback loops for error recovery; checklists for complex processes' rather than anchor 4's 'minor validation gaps' — the batch operations (ADMET filtering, top-20 docking) all carry verification, so the batch-cap at 3 does not apply.

Progressive Disclosure

The body is well-sectioned with clearly signaled one-level-deep pointers ('parameters in TOOLS_REFERENCE.md', 'see REPORT_TEMPLATE.md') and a dedicated Reference Files index describing each file — but scored against the actual bundle, none of the five referenced files (WORKFLOW_DETAILS.md, TOOLS_REFERENCE.md, REPORT_TEMPLATE.md, EXAMPLES.md, CHECKLIST.md) exist; the bundle contains only SKILL.md, so navigation dead-ends and the deferred detail is unavailable. Not anchor 4 ('minor organization gaps') because dangling references are a structural failure, but above anchor 2 since the in-body structure and signaling are good.

Specificity

Multiple concrete actions with comprehensive pipeline coverage, all in third person: 'Discover novel small-molecule binders for protein targets using structure-based and ligand-based screening. Covers druggability assessment, known-ligand mining (ChEMBL, BindingDB), similarity expansion, ADMET filtering, and synthesis feasibility.' Anchor 5 fits — the actions span the whole workflow with named data sources — whereas anchor 4 would require 'minor gaps in coverage'.

Completeness

Explicitly answers both questions: the 'what' is 'Discover novel small-molecule binders for protein targets... Covers druggability assessment, known-ligand mining, similarity expansion, ADMET filtering, and synthesis feasibility', and the 'when' is a concrete 'Use for...' clause ('hit identification, virtual screening, target-to-compounds workflows, and lead-finding before commit-to-medchem'). This matches anchor 5 exactly; anchor 4 would need a weaker or less specific 'when'.

Trigger Term Quality

Good natural-term coverage: 'Use for hit identification, virtual screening, target-to-compounds workflows, and lead-finding before commit-to-medchem' plus 'small-molecule binders for protein targets' — phrases domain users actually say. Not 5 because common synonyms are missing ('drug discovery', 'find inhibitors for a target', 'hit finding'), and not 3 because coverage goes well beyond 'some relevant keywords'.

Distinctiveness Conflict Risk

Clear niche — small-molecule binder discovery anchored by named databases (ChEMBL, BindingDB) — with an explicit boundary against the adjacent skill ('before commit-to-medchem'), and trigger terms (hit identification, virtual screening, lead-finding) that do not plausibly fire for sibling skills like data-wrangling or medchem-optimization. Fits anchor 5's 'clear niche with distinct triggers; minimal conflict risk' rather than anchor 4's 'minor overlap risk'.